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Autosomal-recessive cerebellar ataxias (ARCAs) are clinically and genetically heterogeneous disorders associated with diverse neuro-
logical and nonneurological features that occur before the age of 20. Currently, mutations in more than 20 genes have been identified,
but approximately half of the ARCA patients remain genetically unresolved. In this report, we describe a Japanese family in which two
siblings have slow progression of a type of ARCAwith psychomotor retardation. Using whole-exome sequencing combined with homo-
zygosity mapping, we identified a homozygous missensemutation in SYT14, encoding synaptotagmin XIV (SYT14). Expression analysis
of the mRNA of SYT14 by a TaqMan assay confirmed that SYT14 mRNA was highly expressed in human fetal and adult brain tissue as
well as in the mouse brain (especially in the cerebellum). In an in vitro overexpression system, the mutant SYT14 showed intracellular
localization different from that of the wild-type. An immunohistochemical analysis clearly showed that SYT14 is specifically localized to
Purkinje cells of the cerebellum in humans and mice. Synaptotagmins are associated with exocytosis of secretory vesicles (including
synaptic vesicles), indicating that the alteration of the membrane-traffickingmachinery by the SYT14mutationmay represent a distinct
pathomechanism associated with human neurodegenerative disorders.Hereditary ataxias are genetically heterogeneous neurolog-
ical disorders: autosomal-dominant, autosomal-recessive,
X-linked, and mitochondrial types are known. Among
ataxias, spinocerebellar ataxia (SCA) is relatively common
and involves the cerebellum, brainstem, or spinocerebellar
long tracts.1Autosomal-recessive cerebellar ataxias (ARCAs)
are generally associated with diverse neurological and non-
neurological attributes, resulting in complex phenotypes.
ARCAs include congenital nonprogressive ataxias and
progressive ataxias such as SCAs.2 The clinical onset of
ARCAs usually occurs before the age of 20, even if congen-
ital types are excluded.1,3,4 Currently, more than 20 defec-
tive genes have been identified in ARCAs.2,5,6 These genes
have variable recognized functions, including those in-
volving mitochondrial energy generation, cellular metabo-
lisms, DNA repair, chaperone-mediated protein folding,
RNA processing, and ion channels.1,3,6 Approximately
half of the patients with ARCAs remain genetically un-
resolved.4 Therefore, more investigations of ARCAs are
required. In this study, we describe a Japanese family with
two siblings showing psychomotor retardation and the
slowly progressive type of SCA without involvement of
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fied a causative mutation.
Clinical information and blood materials were obtained
from the family members after written informed consent
was secured. Experimental protocols were approved by
IRBs of the Yokohama City University and the Shinshu
University. Among the children of first-cousin parents,
two siblings (IV-3 and IV-4) were found to be affected,
whereas the other two (IV-1 and IV-2) were healthy
(Figure 1A). No similar patients were recognized within
the family. IV-3 had mild psychomotor retardation from
childhood. He found a job after graduating from an ordi-
nary junior high school. At 35 years of age, he lost his
job for social reasons. Although he had some gait distur-
bances from childhood, he could independently go
shopping and walk a dog even after leaving his occupa-
tion. At the age of ~56, he developed obvious gait unstead-
iness and began to stumble frequently. At 58, he started
to choke on food. These symptoms gradually worsened,
and he sought medical examination at 59 years of age.
He displayed disturbances of smooth-pursuit eye move-
ments, dysarthria, mild limb ataxia, and moderate truncal
ataxia. His muscle tone was normal, and no involuntaryCity University, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan;
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Figure 1. Familial Pedigree, Brain MRI of
Patients, and the SYT14 Mutation Identified
(A) Familial pedigree of the patients with
autosomal-recessive spinocerebellar ataxia. *An
asterisk indicates members whose genomic
DNA was available for this study.
(B) Brain MRI of IV-3 at 59 years of age (left
panels) and IV-4 at 56 years of age (right panels).
Axial (upper panels) and sagittal (lower panels)
sections of a T1-weighted image are shown.
(C) Electropherograms of unaffected (III-1, IV-1,
and IV-2) and affected (IV-3 and IV-4) members,
who show the mutation.
(D) Schematic presentation of SYT14. The red dot
indicates the location of themutation in the C2B
domain.
(E) The missense mutation occurred at an evolu-
tionarily conserved amino acid (in red).movements were observed. Laboratory examination, in-
cluding analysis of serum albumin, vitamin E, and a-feto-
protein, was normal. A nerve-conduction study (NCS)
indicated no neuropathy. No retinitis pigmentosa was
recognized by ophthalmologic evaluation. Brain magnetic
resonance imaging (MRI) revealed mild atrophy of the
cerebellar vermis and hemispheres but no apparent
atrophy of the brain stem or the cerebral cortex. (Figure 1B,
left panels).
Similar to IV-3, IV-4 also had psychomotor retardation
from childhood, but this retardation was more severe
than that of IV-3. After graduation from a school for
disabled children at the age of 15, he entered a facility
for disabled people. He showed gait disorder, but he was
able to walk without a cane. At an age of ~50, his gait
disturbance worsened, and he went for a medical check
at a hospital when he was 56 years old. He displayed distur-
bance of smooth-pursuit eye movements, gaze-evoked
horizontal nystagmus, dysarthria, mild limb ataxia, and
moderate truncal ataxia. No involuntary movements
were observed. His laboratory tests, including those for
serum albumin, vitamin E, and a-fetoprotein, were
normal. NCS was normal. A brain MRI was similar to
that of IV-3 (Figure 1B, right panels). The clinical manifes-
tations of these two patients are summarized in Table 1.
To search for the disease locus, we conducted genome-
wide SNP genotyping of III-1, IV-1, IV-2, IV-3, and IV-4
by using the Genome-wide Human SNP Array 6.0 (SNPThe American Journal of Hum6.0 array) (Affymetrix, Inc., Santa Clara,
CA) according to the manufacturer’s
instructions. Then, SNP 6.0 array data
were subjected to homozygosity mapping
with HomozygosityMapper software.7 For
the linkage analysis, a subset of 7339 SNPs
with high heterozygosity (mean heterozy-
gosity 0.49) was extracted from the SNP
6.0 array data with the program Linkdata-
gen, for which the bin size was set to
0.5cM and the allele frequency of the Japa-
nese population was used.8 The multipointLOD score was calculated with Allegro version 29 on the
basis of the model of autosomal-recessive and X-linked-
recessive inheritance, respectively. In both models, com-
plete penetrance and a disease-allele frequency of 0.0001
were adopted. The homozygosity mapping revealed a
total of three regions, which together were approximately
11.35 Mb in size, as candidate loci, where genes known to
bemutated in ARCA did not exist (Table 2). In themodel of
autosomal-recessive inheritance, a total of ten regions
with a LOD score greater than 1.5 in the multipoint
linkage analysis were identified (Table S1). The three
homozygous regions in accordance with the linked regions
still survived as candidate regions. On the basis of X-linked
recessive inheritance, a total of three regions with positive
LOD scores (maximum LOD score ¼ 0.9031) were high-
lighted; together, these three regions were approximately
101.03 Mb (Table S1).
To find a gene mutation within the candidate loci, we
performed whole-exome sequencing on IV-3 and IV-4.
Three micrograms of genomic DNA was processed with
the SureSelect Human All Exon Kit v.1 (approximately
180,000 exons covering 38 Mb of the CCDS database)
(Agilent Technologies, Santa Clara, CA) according to the
manufacturer’s instructions. Captured DNAs were se-
quenced on an Illumina GAIIx (Illumina, San Diego, CA)
with 76 bp pair-end reads. Of the possible eight lanes of
the flow cell, two lanes for IV-3 and three lanes for IV-4
(Illumina) were used. Image analysis and base callingan Genetics 89, 320–327, August 12, 2011 321
Table 1. Clinical Features of the Patients
Clinical Features IV-3 IV-4
Age at present 61 58
Sex male male
Age of obvious ataxia 56 around 50
Mental retardation mild moderate
Ocular apraxia no no
Ophthalmoplegia no no
Nystagmus no þ
Dysarthria þ þ
Truncal ataxia þþ þþ
Limb ataxia þ þ
Extrapyramidal signs no no
Involuntary movements no no
Sensory involvements no no
Tendon reflex normal-increased normal-decreased
Plantar responses normal normal
Peripheral neuropathy no no
Pes cavus no no
SARAa 12/40 15/40
Cerebellar atrophy
on MRI
þ þ
others normal level of serum
albumin, vitamin E,
and a-fetoprotein
normal level of serum
albumin, vitamin E,
and a-fetoprotein
a SARA: Scale for the assessment and rating of ataxia.32
Table 2. Regions of Homozygosity
Chromosome Chromosomal Position (rsID) Size (Mb) LOD
1 207226930 (rs2761781)–
213992561 (rs1857229)
6.77 2.0537
4 181929079 (rs918401)–
185188999 (rs7690914)
3.26 2.0554
22 45676443 (rs3905396)–
47003473 (rs2013591)
1.33 2.0545
Regions of homozygosity were identified by HomozygosityMapper, and the
LOD scores were calculated by multipoint linkage analysis, for which SNPs
were extracted from SNP 6.0 array data via Linkdatagen.were performed by sequence control software (SCS) real-
time analysis (Illumina) and CASAVA software v1.6 (Illu-
mina). Reads were aligned to the human reference genome
sequence (UCSC hg18, NCBI build 36.1) via the ELAND v2
program (Illumina). Coverage was calculated statistically
with a script created by BITS (Tokyo, Japan). Approxi-
mately 71 million reads from IV-3 and 148 million reads
from IV-4 (these numbers of reads passed quality-control
[Path Filter]) weremapped to the human reference genome
with Mapping and Assembly with Qualities (MAQ)10 and
NextGENe software v2.00 (SoftGenetics, State College,
PA) under the default settings. MAQ aligned 59,491,138
and 126,159,746 reads to the whole genome for IV-3 and
IV-4, respectively. A script created by BITS was used for
extraction of SNPs and indels from the alignment data;
dbSNP build 130 served as a reference for registered SNPs.
A consensus quality score of 40 or more was adopted for
the SNP analysis in MAQ. Coverage analysis revealed that
65.0% (IV-3) and 71.3% (IV-4) of the coding sequences
(CDS) were completely covered (100%), and 77.7% (IV-3)
and 80.3% (IV-4) of CDS were mostly covered by reads
(90% or more) through the whole genome. 79.0% (IV-3)322 The American Journal of Human Genetics 89, 320–327, August 1and 79.7% (IV-4) of total CDS were covered by ten reads
or more (50 reads or more in 66.4% and 77.1%, respec-
tively).
To identify the pathogenic mutation, we adopted a
prioritization scheme, which has been used in recent
studies.11–13 First, we excluded the variants registered in
dbSNP130 from all the detected variants and then picked
up homozygous mutations and variants in coding regions
and the intronic regions within 50 bp from coding
sequences. Of the homozygous mutations and variants,
we focused on those within the candidate regions. As
a result, only two missense mutations or variants,
p.Gly484Asp (c.1451G>A) (NM_001146261.1) in exon 8
of SYT14 (1q32.2, [MIM 610949]) and p.Gln4203Arg
(c.12608A>G) (NM_206933.2) in exon 63 of USH2A
(1q41, [MIM 608400]) remained as candidates for both
cases (Table S2). Sanger sequencing with ABI 3500xL (Life
Technologies, Carlsbad, CA) confirmed that the
c.1451G>A of SYT14 was homozygous in IV-3 and IV-4
and heterozygous in III-1 (father), IV-1, and IV-2, whereas
the c.12608A>G of USH2A was homozygous in IV-2 as
well as IV-3 and IV-4 (Figure 1C and data not shown).
The SYT14 missense mutation occurred at an evolution-
arily conserved amino acid among different species and
resides in the second C2 (C2B) domain (Figures 1D and
1E). In silico analysis incorporating different tools,
including Polyphen, Polyphen2, SIFT, and Align GVGD,
consistently indicated that the change was damaging
(Table S3). The mutation was not detected in 576 Japanese
control chromosomes, indicating that the mutation is very
rare. On the basis of the X-linked recessive model, no path-
ological hemizygousmutation of protein-coding genes was
detected in the possible candidate loci (Table S4).
We considered the SYT14 mutation to be the causative
agent and used the Sanger method to conduct mutation
screening of all the coding regions of SYT14 in 65 simplex
SCA cases and 37 SCA familial cases, including three
with autosomal-recessive inheritance. Only p.Gly183Glu
(c.548G>A) was found in one family with autosomal-
dominant SCA; however, the change was not consistent
with the SCA phenotype in the family (Table S3). Thus,
we could not detect any other pathological changes in
SYT14. This was probably due to the small number of cases
tested.2, 2011
Synaptotagmin XIV (SYT14), which is encoded by
SYT14, is a member of the synaptotagmins (SYTs), which
aremembrane-trafficking proteins, and SYT14 is conserved
across many organisms.14 Although the original report
indicated that SYT14 was not expressed in mouse
brain,14 multiple lines of evidence, including from the
Allen brain Atlas, suggest that SYT14 is expressed in the
central nervous system (CNS) of the fly, mouse, and
human brains.15,16 To confirm SYT14 expression in the
CNS, we performed TaqMan quantitative real-time PCR
analysis with cDNAs of adult human tissue (Human MTC
Panel I, #636742) (Clontech Laboratories, Mountain
View, CA), fetal human tissue (Human Fetal MTC Panel,
#636747) (Clontech Laboratories), mouse tissue (Mouse
MTC Panel I, #636745) (Clontech Laboratories), and
various regions of the mouse brain (GSMBRSET) (NIPPON
Genetics, Tokyo, Japan) as templates. Predesigned TaqMan
probe sets for human SYT14 (Hs00950169_m1), mouse
Syt14 (Mm00805319_m1), human b-actin (ACTB,
4326315E), and mouse Actb (43522341E) from Applied
Biosystems were used. PCR reactions (total volume of
20 ml) contained 10 ml of the TaqMan Gene Expression
Master Mix (Applied Biosystems), 1 ml of 20 3 TaqMan
reagents for ACTB/Actb and SYT14/Syt14, and 1 ml of
cDNA (containing 1 ng cDNA in MTC panels and 25 ng
cDNA in GSMBRSET) as the template. PCR was performed
on a Rotor-Gene Q (QIAGEN, Valencia, CA) as follows:
2 min at 50C and 10 min at 95C, then 40 cycles of
95C for 15 s and 60C for 1 min. Expression levels
were calculated with the Rotor-Gene Q Series Software
(QIAGEN) by the 2DDCt method. The cycling threshold
(Ct) of the target gene was compared with the Ct of
ACTB cDNA, and DCt was expressed as Ct of SYT14  Ct
of ACTB. DDCt was expressed as DCt of the control
sample  DCt of each sample, and relative concentration
was determined as 2-DDCt. Expression in the kidney and
the cerebral cortex was used as the control in Figures 2A–
2D. SYT14 was predominantly expressed in human adult
and fetal brain tissues (Figures 2A and 2B). Even in mice,
substantial expression in the brain was confirmed (but,
not predominant) (Figure 2C). Among various brain
regions in mice, SYT14 was mostly expressed in the cere-
bellum (Figure 2D).
Intracellular distribution of SYT14 in cultured cells was
investigated. The full-length SYT14 PCR product amplified
from human brain cDNA (MHS4426-99239810, Open
Biosystems, Huntsville, AL) was used as a template and
subcloned into pDONR221 (the entry vector of Gateway
system, Invitrogen). We used site-directed mutagenesis to
produce the SYT14 mutant and variants by using a muta-
genesis kit (Toyobo, Osaka, Japan). Variants include
c.611C>T and c.810_812del, which are registered in
dbSNP130, and c.548G>A, which was detected in an SCA
patient with autosomal-dominant inheritance but did
not segregate with the phenotype, indicating that it is
nonpathogenic (Table S3). All constructs were verified by
DNA sequencing. Each construct was recloned into theThe AmericpEF-DEST51 mammalian expression vector (Invitrogen)
and transfected to COS-1 cells with the FuGENER6 trans-
fection reagent (Roche Applied Science, Mannheim,
Germany) according to the manufacturer’s instructions.
Localization of the mutant (p.Gly484Asp) was clearly
different from that of the wild-type and other (normal)
variants. Whereas the wild-type and other variants were
localized to the perinuclear and submembranous regions,
p.Gly484Asp was localized in the cytoplasm (significant
amounts were in the perinuclear region) but formed a
characteristic reticular pattern without showing any sub-
membranous distribution (Figures 2E and S2B). Confocal
microscopic analysis showed that the p.Gly484Aspmutant
was colocalized with an endoplasmic reticulum (ER)
marker, protein disulfide isomerase (PDI), throughout the
cells, whereas the wild-type colocalized with PDI domi-
nantly in perinuclear regions (Figure 2F). immunoblot
analysis combined with subcellular fractionation of the
transfected cells further confirmed that the mutant was
distributed differently from the wild-type. The wild-type
and the mutant (p.Gly484Asp) were distributed in the
nucleus and Golgi apparatus fractions; however, only the
mutant was detected in microsome fractions containing
ER fragments together with an ER membrane marker, cal-
nexin (Figure S1).17 These data suggest that improper
folding of the mutant protein results in abnormal reten-
tion in the ER.
To investigate the effect of the p.Gly484Asp mutation in
the C2B domain on phospholipid binding activity, we
amplified cDNA of C2B domains from the wild-type and
the p.Gly484Asp mutant from SYT14-expressing vectors
by using the following primers: sense, 50-GGATCCGAAA
GTACATCCTCATGTCA-30; and antisense, 50-TCATGAC
TCTAGCAACGCAT-30. We then recloned the cDNA into
Escherichia coli (E. coli) expressing vector (pGEX-4T-3).
The C2B domain of SYT14 fused to glutathione S-trans-
ferase (GST) was expressed in E. coli JM109 and purified
by standard protocols. Both GST-SYT14-C2B (WT) and
GST-SYT14-C2B (p.Gly484Asp) could be mostly purified
of contamination by degradation products, but the
amount of GST-SYT14-C2B (p.Gly484Asp) obtained was
at least four times smaller than that of GST-SYT14-C2B
(WT) (data not shown). Liposome (phosphatidylcholine
and phosphatidylserine, 1:1, w/w) cosedimentation assay
with purified GST-SYT14-C2B was performed as described
previously.18 The result showed that the SYT14-C2B
(p.Gly484Asp) bound liposomes similarly to SYT14-C2B
(WT) (Figure 2G), indicating that the p.Gly484Asp muta-
tion had no effect on the Ca2þ-independent phospho-
lipid-binding activity of the SYT14-C2B domain.
The Allen Mouse Brain Atlas indicates that Syt14 is ex-
pressed inPurkinje cells of the cerebellum inmice; however,
SYT14 localization has not been fully investigated.15 A
rabbit polyclonal anti-SYT14 antibody (Ab-SYT14) was
generated for immunoblotting and immunocytochemistry
(Operon Biotechnologies, Tokyo, Japan) (Figure S2). Immu-
nohistochemical analysis of mouse and human brains wasan Journal of Human Genetics 89, 320–327, August 12, 2011 323
Figure 2. Expression Studies of SYT14/Syt14 cDNA in Human andMouse Tissues and Localization of SYT14 in Transfected COS-1 Cells
(A–D) The results of a TaqMan quantitative real-time PCR assay in which the first-strand cDNA of human adult tissues (A), human fetal
tissues (B), mouse tissues (C), and various regions of mouse brain (D) were used as templates. The relative cDNA concentrations were
determined from cDNA concentrations of the kidney (human adult tissues, human fetal tissues, and mouse tissues) or cerebral cortex
(various regions of the mouse brain). Error bars represent the standard deviation. *S. Muscle indicates skeletal muscle. **E7, **E11,
**E15, and **E17 indicate mouse embryos at 7, 11, 15, and 17 days of embryonic development, respectively. ***Th, Hyp and Po indicate
thalamus, hypothalamus, and pons.
(E) Immunocytochemistry of COS-1 cells transfected with expression vectors of v5/His-tagged wild-type (upper left), p.Gly183Glu
(c.548G>A) (upper middle), p.Pro203Leu (c.611C>T) (upper right), p.Glu270del (c.810_812del) (lower left), or p.Gly484Asp
(c.1451G>A) (lower middle) SYT14. The SYT14 was detected with the anti-v5 antibody (Alexa fluor 488 as the secondary antibody).
Nuclei were stained (white) with 40,6-diamidino-2-phenylindole (DAPI). The horizontal bars indicate 10 mm. The bar graph indicates
the ratio of the cells in which overexpressed proteins were accumulated in submembranous regions. A total of 120 cells per each trans-
fectant in triplicated experiments were counted. Submembranous localization of the mutant (p.Gly484Asp) was mostly unseen, in
contrast to the wild-type (*p < 0.001).
(F) Immunocytochemical analysis of COS-1 cells transfected with expression vectors of v5/His-tagged wild-type (upper panels) or the
p.Gly484Asp mutant (lower panels). The SYT14 was detected with the anti-v5 antibody (Alexa fluor 488 as the secondary antibody),
and PDI (protein disulfide isomerase) was visualized with an anti-PDI antibody (Alexa fluor 546 as the secondary antibody). Nuclei
were stained (white) with DAPI. The scale bar represents 10 mm. The anti-v5 and anti-PDI antibodies and the Alexa-488-conjugated
secondary antibody were all used at a dilution of 1:1000.
(G) Phospholipid binding activity of the C2B domain of the wild-type SYT14 and the p.Gly484Asp mutant. Liposomes and GST-fusion
proteins (2 mg) were incubated in 50 mM HEPES-KOH (pH 7.2) in the presence of 2 mM EGTA for 15 min at room temperature. After
centrifugation at 12,000 3 g for 10 min, the supernatants (non-binding fraction) and pellets (phospholipid-binding fraction) were
separated as described previously.18 The pelleted samples and input samples (100 ng) were subjected to 10% SDS-PAGE followed by
immunoblotting with horseradish peroxidase-conjugated anti-GST antibody (Santa Cruz Biotechnology, Santa Cruz, CA).
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Figure 3. Selective Localization of SYT14 in Purkinje Cells of the Cerebellum in Mice and Humans
(A) Immunohistochemical analysis with the Ab-SYT14 antibody of the cerebellum from an adult mouse at 12 weeks of age. Nuclei were
stained with DAPI (the scale bar represents 100 mm). A magnified image is shown in the first right panel (the scale bar represents
10 mm).The Ab-SYT14 antibody (0.9 mg/dl) was used at a dilution ration of 1:2000, and the Alexa-488-conjugated secondary antibody
dilution was 1:1000.
(B) Immunohistochemical analysis with the Ab-SYT14 antibody of the cerebellum from the human control. Ab-SYT14 antibodies were
preincubated with (left panel) or without (middle panel) peptide antigen before immunostaining. Nuclei were stained with hematoxylin
(scale bars represent 100 mm). A magnified image is shown in the right panel (the scale bar represents 20 mm). The Ab-SYT14 antibody
(0.9 mg/dl) was used at a dilution of 1:500.performed with Ab-SYT14, as previously described.19–21
Mouse brain sections were prepared at the RIKEN Brain
Science Institute. Mouse experimental protocols were
approved by the animal experiment committee of the
RIKENBrain Science Institute. The frozenbrainofC57BL/6J
mouse was mounted in Tissue-Tek and sliced to 10 mm
sections with a freezing microtome. A human adult brain
specimen was obtained through the postmortem examina-
tion of a brain from a control subject without neurodegen-
erative disorders. Informed consent was obtained from
the family on the basis of the IRB-approved protocol of
YokohamaCity University School ofMedicine. The human
brain was fixed in 10% formalin and cut into 1-cm-thick
slices. Sliced tissues were embedded in paraffin wax, and
5 mm sections were immunostained with primary anti-
bodies and visualized with the Vectastain ABC kit (Vector
Laboratories, Burlingame, CA). Selective localization of
SYT14/Syt14 in Purkinje cells of the mouse cerebellum
(Figure 3A) and human cerebellum (Figure 3B) were recog-
nized, indicating that SYT14 plays an important role in
the cerebellum. These data are in agreementwith a scenario
in which the SYT14 mutation causes cerebellar degenera-
tion in this family.
In this study, only one p.Gly484Asp mutation of SYT14
was identified in association with SCA. Quintero-Rivera
et al.16 previously described a 12-year-old female with
cerebral atrophy, absence seizures, developmental delay
with a WISC III score of 58 for full IQ, and de novo
t(1;3)(q32.1;q25.1) disrupting SYT14. Her brain MRI
showed diffuse cerebral atrophy, including that of the cere-The Americbellar hemisphere and vermis. Although the inheritance
modes are different (recessive impact on our family and
dominant on the female patient), mild tomoderate mental
retardation and cerebellar atrophy are common among
patients with SYT14 abnormalities. It will be important
to assess the future phenotype of the female patient
studied by Quintero-Rivera et al.16
Relatively commonARCAs in Japan include ataxia, early-
onset; oculomotor apraxia, hypoalbuminemia/ataxia-
oculomotor apraxia 1 (EAOH/AOA1 [MIM 208920]);
ataxia-oculomotor apraxia 2 (AOA2 [MIM606002]); spastic
ataxia; Charlevoix-Saguenay type (SACS [MIM 270550]);
ataxia with isolated vitamin E deficiency (AVED [MIM
277460]); and ataxia-telangiectasia (AT [MIM 208900]).
(Friedrich ataxia 1 [FRDA (MIM 229300)] has never been
described in the Japanese population.) In this family,
patients never showed ocularmotor apraxia, spasticity,
peripheral neuropathy, retinal abnormality, immunolog-
ical abnormality, or other systemic involvements. As an
adult-onset type of pure ARCA, SYNE1-related ARCA
(also known as spinocerebellar ataxia, autosomal-recessive
8; SCAR8 [MIM610743]) is found tobe causedbymutations
of thegene encoding synapticnuclear envelopeprotein1.22
Furthermore, these patients were not associated with
psychomotor retardation. Thus, SYT14-mutated ARCA,
described here, should be categorized to a distinct type of
ARCA.
SYTs is a large family of transmembrane proteins associ-
ated with exocytosis of secretory vesicles (including syn-
aptic vesicles).23 The mammalian SYT family is composedan Journal of Human Genetics 89, 320–327, August 12, 2011 325
of 17 members. SYTs are anchored to the secretory vesicles
via a single transmembrane domain (TM) close to its N
terminus and have tandem cytoplasmic domains, C2A
and C2B.24 Among SYTs, SYT1 (MIM 185605) is involved
in neurotransmitter release and has been intensively
studied. The crystal structure of the C2 domains consists
of a compact eight-stranded b-barrel with two protruding
loops (loops 1 and 3) that form the Ca2þ-binding
pockets.25 SYT1 binds three and two Ca2þ ions via loops
1 and 3 of C2A and C2B, respectively. Ca2þ binding triggers
the rapid penetration of the C2 domains into membranes
harboring negatively charged phospholipids. Ca2þ also
promotes SYT1 binding to t-SNAREs (target-membrane-
soluble N-ethylmaleimide-sensitive factor attachment
protein receptors). SYT1 is a key sensor for evoked and
synchronous neurotransmitter release in many classes of
neurons.23 SYT14 also has TM, C2A, and C2B domains,
but it has no conserved Ca2þ-binding motif that includes
the conserved aspartic acid residues in loops 1 and 3 of
C2A and C2B.26 Although the roles of SYTs as Ca2þ sensors
have been studied extensively, little is known about
Ca2þ-independent SYTs, which might inhibit the SNARE-
catalyzed fusion in both the absence and presence of
Ca2þ.27 Recently, Zhang et al.28 suggested that Ca2þ-inde-
pendent SYT4 (MIM 600103) negatively regulates exocy-
tosis, regardless of its inability to induce Ca2þ-dependent
exocytosis.
SYT14 has phospholipid-binding activity that is Ca2þ
independent.14 The glycine residue mutated in the family
is located around the C2B domain loop 1, which plays an
important role in binding to phospholipids in SYT1.25 We
confirmed that, compared to the wild-type, the mutation
did not alter the binding activity of SYT14 to phospho-
lipids. In an overexpression system, wild-type SYT14 as
well as normal variants were distributed in the cytoplasm
close to the plasma membrane, showing in-line accu-
mulation along with the membrane. In contrast, the
p.Gly484Asp mutant showed a different (reticular) distri-
bution pattern. In the ER, several cotranslational and
posttranslational modifications that are required for the
correct folding of transmembrane and secretory proteins
take place.29,30 Incompletely folded proteins are generally
excluded from ER exit sites.29 The fact that the
p.Gly484Asp was not properly transferred from the ER
suggests that the mutant protein might not fold correctly.
The lower yield of the mutant protein as compared to the
wild-type in the bacterial expression system we performed
also supports the improper folding of the mutant.
Abnormal distribution in the ER might result in the loss
of function of SYT14 or in ER dysfunction.
In conclusion we have shown that SYT14 is localized
specifically in Purkinje cells of mouse and human cere-
bellum. The results strongly support the involvement of
SYT14 in the pathogenesis of SCA and are consistent
with the atrophy of the cerebellum seen in both patients.
A possible relationship between SYTs and neurodegenera-
tion has been suggested previously,31 and here we provide326 The American Journal of Human Genetics 89, 320–327, August 1data that support the idea that disruption of an SYT protein
is involved in human neurodegeneration and that exocy-
tosis machinery can be involved in one of the pathome-
chanisms of neurodegeneration.Supplemental Data
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